HUTCHMED (China) Limited (H7T1) - Cash Flow Conversion Efficiency

Latest as of December 2022: -0.140x

Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has a cash flow conversion efficiency ratio of -0.140x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-89.37 Million ≈ $-104.48 Million USD) by net assets (€636.87 Million ≈ $744.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HUTCHMED (China) Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

HUTCHMED (China) Limited - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
OVH Groupe SAS PA:OVH	10.219x
UFP Technologies Inc NASDAQ:UFPT	0.089x
Chalet Hotels Limited NSE:CHALET	0.125x
Jiangxi Ganneng Co Ltd SHE:000899	0.116x
Vimian Group AB ST:VIMIAN	0.080x
Shenzhen Changhong Tech SHE:300151	0.045x
Fidelis Insurance Holdings Limited NYSE:FIHL	0.102x
Ocular Therapeutix Inc NASDAQ:OCUL	-0.113x

Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2016–2025)

The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is HUTCHMED (China) Limited worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€1.25 Billion ≈ $1.46 Billion	€-64.66 Million ≈ $-75.59 Million	-0.052x	-8125.01%
2024-12-31	€771.85 Million ≈ $902.38 Million	€497.00K ≈ $581.05K	0.001x	-99.78%
2023-12-31	€743.39 Million ≈ $869.10 Million	€219.26 Million ≈ $256.34 Million	0.295x	+169.93%
2022-12-31	€636.87 Million ≈ $744.57 Million	€-268.60 Million ≈ $-314.02 Million	-0.422x	-114.67%
2021-12-31	€1.04 Billion ≈ $1.22 Billion	€-204.22 Million ≈ $-238.76 Million	-0.196x	-64.27%
2020-12-31	€518.95 Million ≈ $606.71 Million	€-62.07 Million ≈ $-72.56 Million	-0.120x	+53.75%
2019-12-31	€312.90 Million ≈ $365.82 Million	€-80.91 Million ≈ $-94.59 Million	-0.259x	-224.54%
2018-12-31	€412.25 Million ≈ $481.97 Million	€-32.85 Million ≈ $-38.40 Million	-0.080x	-332.07%
2017-12-31	€484.97 Million ≈ $566.98 Million	€-8.94 Million ≈ $-10.46 Million	-0.018x	+60.68%
2016-12-31	€204.06 Million ≈ $238.57 Million	€-9.57 Million ≈ $-11.19 Million	-0.047x	--

About HUTCHMED (China) Limited

F:H7T1 Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.79 Billion

€1.53 Billion EUR

Market Cap Rank

#6697 Global

#967 in Germany

Share Price

€8.90

Change (1 day)

-2.73%

52-Week Range

€8.90 - €15.90

All Time High

€36.80